

1 **Analytical sensitivity of seven SARS-CoV-2 antigen-detecting rapid tests for Omicron**
2 **variant**

3 Meriem Bekliz¹, Kenneth Adea¹, Catia Alvarez¹, Manel Essaidi-Laziosi¹, Camille Escadafal²,
4 Laurent Kaiser^{3,4,5}, Isabella Eckerle^{1,3,5*}

5 ¹Department of Microbiology and Molecular Medicine, University of Geneva, Geneva,
6 Switzerland.

7 ²FIND, Geneva, Switzerland

8 ³Division of Infectious Diseases, Geneva University Hospitals, 1205 Geneva, Switzerland.

9 ⁴Laboratory of Virology, Division of Infectious Diseases and Division of Laboratory Medicine,
10 University Hospitals of Geneva & Faculty of Medicine, University of Geneva, 1205 Geneva,
11 Switzerland.

12 ⁵Geneva Centre for Emerging Viral Diseases, University Hospitals Geneva, and University of
13 Geneva, Switzerland.

14

15 *Corresponding author: Email: Isabella.Eckerle@hcuge.ch

16

17 Keywords

18 SARS-CoV-2; COVID19; Antigen-detecting rapid diagnostic tests; variants of concern;

19 Omicron variant

20

21

22 **Abstract**

23 The emergence of novel SARS-CoV-2 variants of concern (VOCs) requires investigation of a
24 potential impact on diagnostic performance, such as Antigen-detecting rapid diagnostic tests
25 (Ag-RDT). Although anecdotal reports have been circulating that Omicron is in principle
26 detectable by Ag-RDTs, no published data are yet available for the newly emerged Omicron
27 variant. Here, we have performed an analytical sensitivity testing with cultured virus in seven
28 Ag-RDTs for their sensitivity to Omicron compared to data earlier obtained on VOCs Alpha,
29 Beta, Gamma and Delta and a pre-VOC isolate of SARS-CoV-2. Overall, we have found a
30 tendency towards lower sensitivity for Omicron compared to pre-VOC SARS-CoV-2 and the
31 other VOCs across tests. Importantly, while analytical testing with cultured virus may be a
32 proxy for clinical sensitivity, is not a replacement for clinical evaluations which are urgently
33 needed for Ag-RDT performance in Omicron-infected individuals.

34 The emergence of novel SARS-CoV-2 variants of concern (VOCs) requires investigation of a
35 potential impact on diagnostic performance. SARS-CoV-2 antigen-detecting rapid diagnostic
36 tests (Ag-RDT) offer quick, cheap and laboratory-independent results at the point of care.¹
37 Although sensitivity is lower compared to RT-PCR, they enable reliable detection of high viral
38 loads associated with infectious virus presence, making them important public health tools.^{2,3}
39 However, the majority of Ag-RDT validation studies were performed prior to the emergence
40 of SARS-CoV-2 variants of concern (VOC).⁴

41 The VOC Omicron was first reported at the end of November from South Africa and is
42 characterized by a high number of mutations compared to earlier circulating SARS-CoV-2.⁵
43 The majority of mutations are located in the Spike protein, that are, according to preliminary
44 data, associated with considerable escape from neutralization by both disease- and vaccine
45 derived antibodies, and probably also associated lower vaccine effectiveness.^{6,7,8,9,10} Current
46 epidemiological data show that Omicron circulation is associated with a steep increase in case
47 numbers as well as an increased risk of reinfections.¹¹

48 Beyond the Spike mutations, Omicron has also mutations in the nucleocapsid, which is the
49 target of almost all Ag-RDTs. Two mutations found in Omicron are R203K and G204R that
50 have been described already before Omicron in some SARS-CoV-2 sequences, were linked to
51 increased sub-genomic RNA and increased viral loads.¹²⁻¹⁴ In addition, a deletion (Del31-33)
52 is found in the nucleocapsid of Omicron, as well as another mutation P13L, which is present
53 in some, but not all Omicron sequences. No information on a potential impact of these
54 mutations on Ag-RDTs performance is available so far. Anecdotal reports were circulating on
55 positive detection of Omicron-confirmed patient samples by Ag-RDTs but no published data
56 on Ag-RDT sensitivity for Omicron is available so far.

57 Here, we have evaluated test analytical sensitivity using cultured SARS-CoV-2 Omicron
58 variant, in comparison with earlier data on isolates of the other VOCs (Alpha, Beta, Gamma
59 and Delta) and an early-pandemic (pre-VOC) SARS-CoV-2 isolate (B.1.610) in seven Ag-
60 RDTs, three of them WHO-EUL approved.¹⁵⁻¹⁷ All viruses were isolated from clinical samples.
61 Isolates were grown in Vero-E6 cells as described previously.¹⁶ The Omicron variant which
62 was initially isolated on Vero-TMPRSS cells, then further passaged with a stock passage (p2)
63 prepared on VeroE6. Vero TMPRSS were kindly received from National Institute for
64 Biological Standards and Controls (NIBSC, Cat. Nr. 100978). The following mutations and
65 deletion in the nucleocapsid were present in the original patients' sequence as well as in the
66 virus isolate of the passage used in this study: R203K, G204R, P13L, Del31-33. The starting
67 dilution of infectious titers for all viruses used in this study was 4.24 log₁₀ PFU/mL.

68 Seven Ag-RDTs were used: I) Panbio COVID-19 Ag Rapid test device (Abbott); II) Standard
69 Q COVID-19 Ag (SD Biosensor/Roche); III) Sure Status (Premier Medical Corporation), the
70 three latter being WHO-EUL approved and thus of high global public health relevance,¹⁸ IV)
71 2019-nCoV Antigen test (Wondfo); V) Beijing Tigsun Diagnostics Co. Ltd (Tigsun); VI) Onsite
72 COVID-19 Ag Rapid Test (CTK Biotech); VII) ACON biotech (Flowflex), several of them
73 being on the waiting list for WHO-EUL approval.

74 All Ag-RDT assays were performed according to the manufacturers' instructions with the
75 exception that 5 µL of virus dilution was directly added to the proprietary buffer, and then
76 applied to the Ag-RDT in duplicates under BSL3 conditions.¹⁷ Ag-RDT buffer without virus
77 was used as a negative control. Any visible test band in the presence of a visible control band
78 was considered as positive.

79 When assessing by infectious virus titers (PFU/mL) (**Fig 1**), analytical sensitivity to detect
80 Omicron was lower than for the other VOCs in most of the tests evaluated. One test, Flowflex

81 (ACON biotech) showed the highest overall sensitivity for all SARS-CoV-2 isolates used
82 compared to the others, and here, Omicron was detected with even slightly higher sensitivity
83 than Delta but still lower than Alpha, Beta, Gamma and pre-VOC SARS-CoV-2.

84 Of note, while in this analysis the previous VOCs Alpha, Beta, Gamma and Delta were mainly
85 detected with comparable or even higher sensitivity compared to pre-VOC SARS-CoV-2, here
86 Omicron is the first VOC which showed a tendency towards lower analytical sensitivity across
87 assays. However, we have also observed considerable heterogeneity in sensitivity patterns
88 across variants and between individual assays in this analytical testing using cultured virus.

89 Differences in analytical sensitivity between Ag-RDTs might be explained by the different
90 epitopes used in each test, potentially affected by the mutations in the nucleocapsid. If the lower
91 sensitivity towards Omicron that we observed here is confirmed by findings from clinical
92 validations, the use of Ag-RDTs in the early symptomatic period of an Omicron infection or in
93 asymptomatic patients could be less reliable, with important implications for public health
94 measures.

95 Importantly, while analytical testing with cultured virus may be a proxy for clinical sensitivity,
96 is not a replacement for clinical evaluations and has several limitations, e.g. ratio between
97 infectious virus, viral protein and RNA copies might differ between patient specimens and
98 cultured virus isolates. In addition, other factors, such as *in vivo* shedding of infectious virus
99 and overall viral loads could further influence clinical test performance. Therefore, further
100 studies on diagnostic accuracy of Ag-RDTs for the newly emerged VOC Omicron are urgently
101 needed to guide public health responses.

102 **Funding**

103 This work was supported by the Swiss National Science Foundation (grant number 196383),
104 the Fondation Ancrage Bienfaisance du Groupe Pictet, and FIND, the global alliance for
105 diagnostics. The Swiss National Science Foundation and the Fondation Ancrage Bienfaisance
106 du Groupe Pictet had no role in data collection, analysis, or interpretation. Antigen rapid
107 diagnostic tests were provided by FIND and FIND was involved in methodology, data analysis
108 and interpretation. CE is an employee of FIND.

109

110 **Acknowledgments**

111 We thank Silvio Steiner, Jenna Kelly and Volker Thiel for sequencing of the Omicron isolate.

112

113 **Conflicts of Interest**


114 The authors declare no competing interests.

115 References

- 116 1. Nordgren J, Sharma S, Olsson H, et al. SARS-CoV-2 rapid antigen test: High sensitivity to
117 detect infectious virus. *J Clin Virol* 2021; **140**: 104846.
- 118 2. World Health Organization (WHO) Antigen-Detection in the Diagnosis of SARS-CoV-2
119 Infection Using Rapid Immunoassays. [(accessed on 28 April 2021)]; Available online:
120 [https://www.who.int/publications/i/item/antigen-detection-in-the-diagnosis-of-sars-cov-](https://www.who.int/publications/i/item/antigen-detection-in-the-diagnosis-of-sars-cov-2infection-using-rapid-immunoassays)
121 [2infection-using-rapid-immunoassays](https://www.who.int/publications/i/item/antigen-detection-in-the-diagnosis-of-sars-cov-2infection-using-rapid-immunoassays).
- 122 3. Mina MJ, Parker R, Larremore DB. Rethinking Covid-19 Test Sensitivity - A Strategy for
123 Containment. *N Engl J Med* 2020; **383**(22): e120.
- 124 4. WHO Weekly epidemiological update on COVID-19.
125 [https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---10-](https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---10-august-2021)
126 [august-2021](https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---10-august-2021) Date: August, 10 2021.
- 127 5. World Health Organization. [https://www.who.int/en/activities/tracking-SARS-CoV-2-](https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/)
128 [variants/](https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/) (accessed 08.12.2021).
- 129 6. Wilhelm A, Widera M, Grikscheit K, et al. Reduced Neutralization of SARS-CoV-2 Omicron
130 Variant by Vaccine Sera and monoclonal antibodies. *medRxiv* 2021: 2021.12.07.21267432.
- 131 7. Cele S, Jackson L, Khan K, et al. SARS-CoV-2 Omicron has extensive but incomplete escape
132 of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection. *medRxiv* 2021:
133 2021.12.08.21267417.
- 134 8. Rössler A, Riepler L, Bante D, Laer Dv, Kimpel J. SARS-CoV-2 B.1.1.529 variant (Omicron)
135 evades neutralization by sera from vaccinated and convalescent individuals. *medRxiv* 2021:
136 2021.12.08.21267491.
- 137 9. Dejnirattisai W, Shaw RH, Supasa P, et al. Reduced neutralisation of SARS-COV-2 Omicron-
138 B.1.1.529 variant by post-immunisation serum. *medRxiv* 2021: 2021.12.10.21267534.
- 139 10. Gardner BJ, Kilpatrick AM. Estimates of reduced vaccine effectiveness against hospitalization,
140 infection, transmission and symptomatic disease of a new SARS-CoV-2 variant, Omicron
141 (B.1.1.529), using neutralizing antibody titers. *medRxiv* 2021: 2021.12.10.21267594.
- 142 11. Pulliam JRC, van Schalkwyk C, Govender N, et al. Increased risk of SARS-CoV-2 reinfection
143 associated with emergence of the Omicron variant in South Africa. *medRxiv* 2021:
144 2021.11.11.21266068.
- 145 12. Covariants. 2021. <https://covariants.org/per-country> (accessed 09.12.2021).
- 146 13. Leary S, Gaudieri S, Parker MD, et al. Generation of a novel SARS-CoV-2 sub-genomic RNA
147 due to the R203K/G204R variant in nucleocapsid. *bioRxiv* 2021: 2020.04.10.029454.
- 148 14. Mourier T, Shuaib M, Hala S, et al. Saudi Arabian SARS-CoV-2 genomes implicate a mutant
149 Nucleocapsid protein in modulating host interactions and increased viral load in COVID-19
150 patients. *medRxiv* 2021: 2021.05.06.21256706.
- 151 15. FIND. 2021. <https://www.finddx.org/sarscov2-eval-antigen/> (accessed 17.12.2021).
- 152 16. Bekliz M, Adea K, Essaidi-Laziosi M, et al. SARS-CoV-2 antigen-detecting rapid tests for the
153 delta variant. *Lancet Microbe* 2021.
- 154 17. Bekliz M, Adea K, Essaidi-Laziosi M, et al. SARS-CoV-2 rapid diagnostic tests for emerging
155 variants. *Lancet Microbe* 2021; **2**(8): e351.
- 156 18. World Health Organization. 2021.
157 [https://extranet.who.int/pqweb/sites/default/files/documents/211125_EUL_SARS-CoV-](https://extranet.who.int/pqweb/sites/default/files/documents/211125_EUL_SARS-CoV-2_products_list.pdf)
158 [2_products_list.pdf](https://extranet.who.int/pqweb/sites/default/files/documents/211125_EUL_SARS-CoV-2_products_list.pdf).

159

160 **Figure 1**



161

162 Heat map based on Log₁₀ PFU/mL for analytical sensitivity of seven Ag-RDTs assays with an
163 early-pandemic SARS-CoV-2 isolate (B.1.610), the VOCs Alpha, Beta, Gamma and Delta in
164 comparison Omicron.

165 Ag-RDTs used: I) Panbio COVID-19 Ag Rapid test device (Abbott); II) Standard Q COVID-
166 19 Ag (SD Biosensor/Roche); III) Sure Status (Premier Medical Corporation); IV) 2019-nCoV
167 Antigen test (Wondfo); V) Beijing Tigsun Diagnostics Co. Ltd (Tigsun); VI) Onsite COVID-
168 19 Ag Rapid Test (CTK Biotech); VII) Flowflex (ACON Biotech).

169 Analytical sensitivity for early-pandemic SARS-CoV-2 B.1.610, Alpha, Beta, Gamma and
170 Delta have already been published before but were added here for consistency reasons and
171 better interpretability of the data on Omicron.^{15,16}